[REVISION HISTORY]

Eli Lilly market growth and pharmaceutical expansion

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-15 19:21 UTC → 2026-10-01 21:12 UTC · added ~~removed~~

Eli Lilly has experienced significant financial growth and market recognition driven by its diabetes and weight-loss medication portfolio. Analysts have issued upgrades and high price targets, with Citigroup setting a $1,600 target based on the company’s “dominant 60% share of the global weight-loss medication market.” Berenberg also elevated its rating from Hold to Buy, setting a $1,400 price target. This momentum led Eli Lilly to become the first healthcare company to reach a $1 trillion market capitalization. The company’s financial performance is heavily concentrated in its tirzepatide-based products, Mounjaro and Zepbound, which accounted for nearly 65% of total revenue following a 48% year-over-year increase in second-quarter revenue to $23 billion. While growth remains strong, analysts have noted potential risks regarding brand concentration and competition from rival GLP-1 therapies. Despite investor concerns regarding declining realized prices due to rebates and competitive pricing, Eli Lilly has raised its full-year revenue guidance to a range of $85 billion to $87 billion. The company’s metabolic portfolio continues to expand, bolstered by the April 2026 approval of the oral obesity pill Foundayo. Looking forward, the company is developing retatrutide, a weekly injection targeting three receptors for weight loss, which is expected to undergo regulatory application in early 2027.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.